Clinical Trial Update: Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ladarixin as adjunctive therapy to improve glycemic control in Type 1 diabetes was terminated, with results posted on February 3, 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Ladarixin (ladarixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Type 1 Diabetes | Phase 2 | Status: TERMINATED | Results posted: 2025-02-03